Paul R. Kirchgraber - 21 Feb 2023 Form 4 Insider Report for LABORATORY CORP OF AMERICA HOLDINGS (LH)

Role
CEO, Covance Drug Development
Signature
/s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber
Issuer symbol
LH
Transactions as of
21 Feb 2023
Net transactions value
-$1,457,145
Form type
4
Filing time
23 Feb 2023, 08:54:27 UTC
Previous filing
14 Feb 2023
Next filing
03 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LH Common Stock Options Exercise $547,530 +3,000 +21% $182.51 17,069 21 Feb 2023 Direct
transaction LH Common Stock Sale $2,004,675 -8,000 -47% $250.58 9,069 21 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LH Non-qualified Stock Options Options Exercise $0 -3,000 -41% $0.000000 4,300 21 Feb 2023 Common Stock 3,000 $182.51 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price of $250.5844 per share represents a weighted average of sales prices ranging from $250.44 to $250.79 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a securityholder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
F2 Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
F3 The option vested in three equal annual installments beginning on the date reflected in this column.